Retatrutide ‘GLP-3’ Late-Stage Data: Triple Agonist Nears 20-25% Weight Loss
Retatrutide, an unapproved triple-receptor agonist nicknamed GLP-3, is in late-stage trials with attributed 70-pound and 20-25% weight-loss figures, while illegal Reta sales draw FDA letters.
Read article →